News

Filter

Current filters:

Interviews

1 to 9 of 55 results

Genesis One Nucleus 2014: personalized medicine and big data

Genesis One Nucleus 2014: personalized medicine and big data

10-12-2014

In the opening sessions at the Genesis One Nucleus 2014 conference in London yesterday, the main themes…

Evidence-based medicineHealth Medical PharmaInterviewsJohnson & JohnsonPharmaceuticalResearch

"My staff are involved in setting the global healthcare agenda:" interview with Parexel's Thomas Senderovitz

08-12-2014

With so many balls to juggle in the development pathway of a new drug, pharma companies looking for support…

InterviewsParexelParexelPharmaceuticalResearchThomas Senderovitz

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

Turning a constraint into an enabler: transparency round-table at Veeva's commercial summit 2014

05-12-2014

In one of the opening sessions, cloud-based life sciences provider Veeva’s co-founder and president…

BMI SystemEuropeInterviewsPharmaceuticalRegulationVeeva

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

27-11-2014

John Andrews, consultant editor of The Economist, opened the Global Crisis of Depression conference by…

InterviewsLundbeckNeurologicalPharmaceuticalResearchSocial IssuesUK

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

07-11-2014

The breakthrough achieved by Dutch bacterial specialist Micreos is the most promising development the…

Antibiotics and Infectious diseasesBiosimilarsBiotechnologyInterviewsMicreosNetherlandsResearchStaphefekt

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

30-09-2014

An orphan drug could offer real hope to patients with rare thyroid cancer, Japanese drugmaker Eisai revealed…

EisaiInterviewsJapanlenvatinibOncologyPharmaceuticalResearch

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

EXPERT VIEW: Utilizing supplementary protection certificates for active ingredients in the pharma industry

29-09-2014

Intellectual Property can be vital for the success of any pharmaceutical invention. It is very important…

EuropeInterviewsLegalPatentsPharmaceuticalUnited Kingdom

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

1 to 9 of 55 results

COMPANY SPOTLIGHT

Menarini

Back to top